Global Autoimmune Hepatitis Diagnosis and Treatment Market Size, Share & Trends Analysis Report By Diagnosis ( Blood Test, Imaging Test, Liver Biopsy) By Treatment ( Medication, Corticosteroids, Immune System Suppressors, Liver Transplant), By Type (Type-I, Type-II, Variant AIH) End-User (Hospitals & Clinics, Diagnostic Centre, and Research Institutions) Forecast Period 2022-2028
The global autoimmune hepatitis diagnosis and treatment market are anticipated to grow at a CAGR of around 5.7% during the forecast period. Autoimmune hepatitis is a long-lasting chronic disease that is caused when the immune system of the body arracks the normal cells and results in liver damage. The disease develops as a result of an inherited tendency or genetic predisposition, which increases the demand for autoimmune hepatitis medication. The factors attributing to the growth of the market include rising initiatives by major market players to develop highly sensitive and rapid tests to detect liver associated diseases and changing lifestyles where an increase in consumption of alcohol is causing severe liver diseases. However, The strict regulation for liver transplantation is a serious hindrance to the growth of the autoimmune hepatitis diagnosis and treatment market.
Impact of COVID-19 on Global Autoimmune Hepatitis Diagnosis and Treatment Market
A growing number of COVID-19 cases have been linked to Autoimmune Hepatitis and liver diseases. The reasons for liver injury during the COVID-19 can be attributed to different factors that include hypoxia, hepatic congestion, drug-induced liver diseases, and virus-induced systematic inflammation. The patients with cirrhosis, COVID-19 has been linked to hepatic decompensation and resulting liver-related mortality. However, COVID19's impact on healthcare resources had a negative impact on the delivery of care and the outcomes of patients with chronic liver disease. As a result, there has been a decrease in the treatment, diagnosis, and follow-up of patients with liver disease, which had a partial negative impact on the healthcare industry during the pandemic.
The global autoimmune hepatitis diagnosis and treatment market are segmented based on diagnosis, treatment, types, and end-user. Based on the diagnosis, the market is segmented into blood tests, imaging tests, and liver biopsy. Based on treatment, the market is segmented into Medication, corticosteroids, immune system suppressors, liver transplants. Further, based on type the market is segregated into Type-I, Type-II, Variant AIH. Furthermore, on the basis of end-user, the market is classified into hospitals & clinics, diagnostic centers, and research institutions.
Global Autoimmune Hepatitis Diagnosis and Treatment Market Share by Diagnosis, 2020 (%)
Global Autoimmune Hepatitis Diagnosis and Treatment Market Share
The imaging test is projected to hold a significant share in the global Autoimmune Hepatitis Diagnosis and Treatment market
Among diagnosis, the imaging test segment is projected to have a significant share in the global market. This is due to an increase in the number of initiatives undertaken by key players in the market for liver disease diagnostics to develop advanced imaging techniques. Moreover, the factors such as the growing demand for early disease detection and the widening scope of clinical applications, as well as the rapidly growing geriatric population with such chronic disorders will be also attributing to the growth of the segment. An imaging test, includes X-ray, ultrasound, Magnetic Resonance Imaging (MRI) scan, Computed Tomography (CT) scan, and other methods.
The global autoimmune hepatitis diagnosis and treatment market are further segmented based on geography including North America, Europe, Asia-Pacific, and the Rest of the World. Due to a high prevalence rate of urinary tract infections, North America is projected to have a significant share in the global market. Increased alcoholic beverage consumption, illegal drug intake, an increase in the prevalence of liver diseases, and rising government and private awareness programs have all contributed to the growth of the North American autoimmune hepatitis diagnosis and treatment market. However, stringent regulatory approvals for liver disease treatment drugs and vaccines, as well as resistance to antiviral drugs being used for hepatitis B and hepatitis C treatment, restrict the market to some extent.
Global Autoimmune Hepatitis Diagnosis and Treatment Market Growth, by Region 2022-2028
Global Autoimmune Hepatitis Diagnosis and Treatment Market region
Asia-Pacific is projected to grow significantly in the global Autoimmune Hepatitis Diagnosis and Treatment market
Geographically, Asia-Pacific is estimated to have considerable CAGR in the global Autoimmune Hepatitis Diagnosis and Treatment market during the forecast period. The growth is attributed to the increasing percentage of the aged population diagnosing liver-related diseases is the major factor driving the growth of the market. Further, high R&D investments and the presence of key players are also some of the factors expected to drive the growth of the region's market for autoimmune hepatitis diagnosis and treatment. However, stringent regulations of the FDA and MHRA for approval of drugs, high cost associated with the development of new drugs, high cost involved in the treatment of autoimmune hepatitis diagnosis will be restraining the growth of the Asia-Pacific autoimmune hepatitis diagnosis and treatment market.
Market Players Outlook
The key players of the autoimmune hepatitis diagnosis and treatment market include Gilead Lifesciences, Inc., Merck & Co., Inc., Bio-Rad Laboratories, Inc. Novartis International AG, Abbott Laboratories, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers, and acquisitions, collaborations, and new product launches, to stay competitive in the market. For instance, in September 2020, Pfizer Inc announced a strategic collaboration agreement Vivet Therapeutics. Under this agreement, Pfizer will supply clinical supplies for a Phase 1/2 clinical trial by assessing Vivet's proprietary investigational gene therapy, VTX-801, for the potential cure of Wilson disease, a rare and potentially fatal liver disorder. This collaboration with Vivet highlights the importance of Pfizer’s strategic investments in end-to-end gene therapy research and supply to support the timely delivery of these critical new therapies for patients.
The Report Covers
- Market value data analysis of 2020 and forecast to 2027.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global Autoimmune Hepatitis Diagnosis and Treatment market
- Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying 'who-stands-where in the market.
Table of Contents
- Current Industry Analysis and Growth Potential Outlook
- Impact of COVID-19 on the Global Autoimmune Hepatitis Diagnosis and Treatment Industry
- Recovery Scenario of Global Autoimmune Hepatitis Diagnosis and Treatment Industry
1.2.1. By Segments
1.2.2. By Geography
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on key players
5.1.1. Blood Test
5.1.2. Imaging Test
5.1.3. Liver Biopsy
5.2. Global Autoimmune Hepatitis Diagnosis and Treatment market by Treatment
5.2.3. Immune System Suppressors
5.2.4. Liver Transplant
5.3. Global Autoimmune Hepatitis Diagnosis and Treatment market by Type
5.3.3. Variant AIH
5.4. Global Autoimmune Hepatitis Diagnosis and Treatment market by End-User
5.4.1. Hospitals and Clinics
5.4.2. Diagnostic Centre
5.4.3. Research Institutions
6.1.1. United States
6.2.6. Rest of Europe
6.3.4. South Korea
6.3.5. Rest of Asia-Pacific
6.4. Rest of the World
A selection of companies mentioned in this report includes:
- Abbott Laboratories,
- AbbVie, Inc.
- Arihantanam Life Care Pvt Ltd.
- AstraZeneca PLC
- Bayer AG
- Biocon, Ltd.
- Bio-Rad Laboratories, Inc.
- Bristol-Myers Squibb Co.
- Cipla, Ltd.
- GlaxoSmithKline PLC
- Gilead Lifesciences, Inc.
- Johnson & Johnson Services, Inc.
- Inova Diagnostics, Inc.
- Merck & Co., Inc.
- Novartis International AG
- Organovo Holdings, Inc.
- Pfizer, Inc.
- Upcyte Technologies GmbH